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Allogeneic hematopoietic cell transplantation is a potential curative treatment option for var-
ious malignant and nonmalignant hematologic disorders. Patients undergoing an allogeneic
hematopoietic cell transplant are prescribed immune-suppressant therapies to facilitate
hematopoietic donor-cell engraftment and prevent graft-versus-host disease. Drug–drug inter-
actions may occur, owing to exposure to complex multidrug regimens with narrow therapeutic
windows and high toxicity profiles. Here, we describe a unique case of a 65-year-old man with
poor-risk acute myeloid leukemia who underwent a matched-sibling hematopoietic cell allo-
graft. Sirolimus and tacrolimus were used for graft-versus-host disease prophylaxis. He devel-
oped oral thrush requiring treatment with clotrimazole troches, which subsequently resulted in
serious renal toxicity attributed to supratherapeutic levels of sirolimus and tacrolimus. Patient
renal function improved after temporarily holding both immune suppressants, and administer-
ing phenytoin to help induce sirolimus and tacrolimus metabolism. This case highlights suddenve, FOB-3,
158 J. El-Asmar et al.and serious toxicities that resulted from clotrimazole–sirolimus and clotrimazole–tacrolimus
drug–drug interactions, even when administered topically.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is
a potential curative treatment option for various malignant
and nonmalignant hematologic disorders [1–5]. Patients
undergoing allo-HCT are prescribed immune suppressive
therapies to facilitate hematopoietic donor-cell engraft-
ment and prevent graft-versus-host disease (GVHD) [6].
For several years, the combination of a calcineurin inhibi-
tor, namely cyclosporine, with methotrexate was the most
commonly used regimen to prevent acute GVHD. Later, data
showed a lower incidence of Grades 2–4 acute GVHD when
using tacrolimus versus cyclosporine in unrelated donor allo-
grafting [7]. Combining tacrolimus with sirolimus has
become a popular regimen for GVHD prophylaxis at various
transplant programs worldwide, owing to a lower incidence
of severe mucositis when compared to methotrexate
[8–10].
During allo-HCT, it is imperative to maintain blood levels
of immune suppressants within a desirable therapeutic
range to ensure engraftment, prevent GVHD, and avoid
drug-related toxicity and consequent morbidity [11].
Drug–drug interactions may occur as a result of exposure
to medications with narrow therapeutic windows and high
toxicity profiles. Understanding the mechanism(s) associ-
ated with metabolism of such drugs is important to help
avoid unwanted and potentially serious drug–drug interac-
tions [11].
Tacrolimus (FK506), a calcineurin inhibitor, is primarily
metabolized by the CYP4503A4 system in the liver and
intestinal wall, and is well-known for its inter- and intra-
patient pharmacokinetic variability [12]. Sirolimus, an inhi-
bitor of the mammalian target of rapamycin (MTOR)
enzyme, exerts its function by reducing DNA transcription
and translation, and inducing cell cycle arrest in the G1
phase in activated lymphocytes, among others [11]. Similar
to tacrolimus, sirolimus is predominantly metabolized by
the hepatic CYP4503A4 [13,14].
Azole antifungal agents are CYP3A4 inhibitors commonly
used in the setting of allo-HCT for anti-fungal prophylaxis
and treatment of fungal infections [15–20]. Systemic tria-
zoles, such as fluconazole, posaconazole, and voriconazole,
are used consistently in allo-HCT patients to inhibit fungal
cytochrome P450 14-a-sterol demethylase [21]. Drug–drug
interactions with these agents are well documented for
CYP3A4 inhibition, requiring dose reductions in other con-
comitant CYP3A4-substrate medications by 25–90%,
depending on which azole antifungal is being prescribed
[11]. Inhibition of CYP450 enzymes by azole antifungals pri-
marily occurs through intestinal and hepatic CYP3A4. Con-
flicting data regarding inhibitory or inducing effects of
oral clotrimazole exist between laboratory and human stud-
ies [21]. However, oral administration of a CYP3A4 substratein combination with clotrimazole may result in the inhibi-
tion of presystemic (intestinal) versus systemic (hepatic)
metabolism by CYP3A4 [21].
Empiric dose-reduction of calcineurin inhibitors and siro-
limus is necessary when azole antifungals are prescribed
[11]. Vigilant monitoring of immunosuppressant blood levels
is imperative to ensure therapeutic benefit and avoid toxic-
ities. Several case reports have described renal toxicity
occurring when combining azoles with calcineurin inhibitors
or sirolimus [22–25]. The potential adverse drug–drug
interaction between oral clotrimazole troches and tacroli-
mus was anecdotally described in a liver-transplant recipi-
ent [26]. Here, we present the first case, to our
knowledge, of an allo-HCT recipient who developed acute
kidney injury as a result of elevated levels of both sirolimus
and tacrolimus following use of clotrimazole troches for
treatment of oral thrush.
Case report
A 65-year-old man with poor-risk acute myeloid leukemia
with associated complex karyotype underwent an allo-HCT
in first complete remission from a human leukocyte
antigen-matched-sibling donor (Class I: A–C; Class II:
DRB1) using granulocyte-colony stimulating factor-
mobilized peripheral blood stem cells. The HCT-
comorbidity index of the patient at the time of transplanta-
tion was two [27]. The preparative regimen for allo-HCT
consisted of 40 mg/m2 intravenous fludarabine (Day 5,
Day 4, Day 3, and Day 2) and 130 mg/m2 intravenous
busulfan aimed at a target area-under-the curve (AUC) dose
of 3,500 mmol min/L per dose  four doses (Day 5, Day
4, Day 3, and Day 2). GVHD prophylaxis consisted of
tacrolimus started on Day 3 at a dose of 0.01 mg/kg (ideal
body weight), given initially as a 24-hour continuous intra-
venous infusion and later converted to an oral formulation
using a 1:4 ratio on Day +12 post-allografting. A 12-mg load-
ing dose of sirolimus was given on Day 1, followed by
4 mg/d beginning on Day 0. The immunosuppressant-goal
range for tacrolimus was 3–7 ng/mL, and 8–14 ng/mL
for sirolimus. Antimicrobial prophylaxis consisted of
800 mg acyclovir orally twice a day, 400 mg ciprofloxacin
orally twice a day, and 50 mg micafungin once daily, started
on Day 0. The dose of infused CD34 cells was 9.41  106/kg
of recipient body weight. The clinical course of the patient
was complicated by diarrhea associated with Clostridium
difficile, which developed on Day 2 and required 125 mg
vancomycin orally four times per day. On Day +9 post-
transplantation, the patient developed oral mucositis,
which progressed to Grade 3 by Day +12 and required
intravenous hydromorphone for pain control. On Day +15,
the patient had evidence of oral thrush. At that time, the
oral mucositis had improved slightly, and there were no
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Clotrimazole troches, sirolimus, tacrolimus 159ulcerative lesions on the oral mucosa or the tongue. The
patient was prescribed 10 mg clotrimazole troches (Perrigo,
Minneapolis, MN, USA) orally five times per day. By Day +17,
there was near resolution of the thrush. By Day +18, it was
noted that his serum sirolimus levels had increased by at
least 2-fold (from 13.1 ng/mL to >30.0 ng/mL), and his
tacrolimus levels had increased nearly four-fold (from
4.6 ng/mL to 17.2 ng/mL; Figs. 1 and 2). The serum crea-
tinine level increased from a baseline of 0.7–1.2 mg/dL,and reached a peak level of 3.2 mg/dL by Day +20 (Fig. 3).
Sirolimus and tacrolimus doses were held on Day +18, and
clotrimazole troches were discontinued at that time,
although tacrolimus and sirolimus levels remained elevated
(Figs. 1 and 2). Phenytoin (300 mg, orally) was administered
on Day +20 and Day +23 to accelerate CYP3A4 metabolism
of sirolimus and tacrolimus. By Day +24, the serum
creatinine measurement in the patient had decreased to
2.3 mg/dL, and immunosuppresant levels normalized within
Day 0
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Fig. 3 Creatinine level.
160 J. El-Asmar et al.therapeutic ranges (tacrolimus level decreased to
6.1 ng/mL, and the sirolimus level to 13.1 ng/mL). The
patient also developed evidence of sinusoidal obstructive
syndrome (SOS) on Day +25, requiring placement of an
intraperitoneal shunt for management of ascites. During
the period of supratherapeutic immunosuppressant levels
and acute renal failure, the patient did not require
hemodialysis and continues to recover well from the seque-
lae of SOS. Both tacrolimus and sirolimus were restarted on
Day +27 at 0.5 mg daily and 1 mg daily, respectively.
Discussion
Recognition of clinically significant interactions with
immunosuppressant therapy is essential to minimize toxicity
and maximize therapeutic efficacy. Azole antifungals inhibit
CYP3A4 and, accordingly, require major dosage modifica-
tions of immunosuppressants, such as sirolimus and tacroli-
mus. The systemic absorption of oral clotrimazole troches is
highly variable and unpredictable, as noted by conflicting
results of its inhibitory effects in vitro versus in vivo. In
our case, using the Drug Interaction Probability Scale as
published by Horn et al. [28], we demonstrated a probable
drug interaction between clotrimazole troches and sirolimus
or tacrolimus. The scores for each particular drug–drug
interaction, namely clotrimazole troches-sirolimus and
clotrimazole troches-tacrolimus, were seven and seven,
respectively [28].
Shord et al [21]. demonstrated the inhibitory effects of
oral clotrimazole prescribed three times daily for five days,
and administered with oral versus intravenous midazolam (a
CYP3A4-surrogate probe) in a randomized open-label cross-
over study in healthy volunteers. Co-administration of a
strong CYP3A4 substrate (midazolam) in combination with
clotrimazole troches resulted in reduction of oral midazo-
lam clearance by 40%, and a 40% increase in AUC [21].Intravenous midazolam administration was unaffected.
These data suggested that concomitant use of oral clotrima-
zone with an oral CYP3A4 substrate can substantially alter
the bioavailability of such medications.
Unlike systemic triazoles, where interactions with
immunosuppressants are well described, the impact of oral
clotrimazole on the pharmacokinetics of these medications
may be underestimated due to its low systemic concentra-
tion. Here, we demonstrated the potential clinical effects
of clotrimazole troches on sirolimus and tacrolimus in an
allo-HCT recipient who developed oral thrush. In this case,
the patient developed supratherapeutic levels of tacrolimus
and sirolimus within a short 3-day period, which resulted in
serious, but reversible, acute kidney injury. Throughout the
transplant procedure, the fluid balance of the patient was
closely monitored and maintained with intravenous fluids
as best as possible in a euvolemic state, hence making dehy-
dration a less plausible cause of his renal failure. The
patient received phenytoin to expedite the CYP3A4 metabo-
lism of sirolimus and tacrolimus. Improvement of renal
function did not occur until 1 week after clotrimazole was
discontinued.
Our case highlights this potentially serious interaction
between clotrimazole oral troches and systemic sirolimus
and tacrolimus, and certainly the need for dose adjustment
when utilizing these drugs concomitantly.
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